HC Wainwright Has Bullish Outlook for DTIL FY2026 Earnings

Key Points

• HC Wainwright raised its FY2026 EPS estimate to a loss of $2.01 from a loss of $3.47 and maintained its Buy rating; the consensus estimate is a loss of $2.60.
• The analyst lowered its earnings outlook for FY2027–FY2029 and reduced its FY2030 profit estimate, tempering the improved FY2026 forecast.
• Precision BioSciences reported a quarterly loss of $0.28 per share, beating the $0.85 loss analysts expected, though revenue of $1.25 million fell short of estimates.

Precision BioSciences, Inc. (NASDAQ:DTIL - Free Report) - Investment analysts at HC Wainwright increased their FY2026 earnings estimates for shares of Precision BioSciences in a research report issued on Thursday, November 5th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings of ($2.01) per share for the year, up from their prior forecast of ($3.47). HC Wainwright has a "Buy" rating on the stock. The consensus estimate for Precision BioSciences' current full-year earnings is ($2.60) per share. HC Wainwright also issued estimates for Precision BioSciences' Q4 2026 earnings at ($0.72) EPS, Q1 2027 earnings at ($0.42) EPS, Q2 2027 earnings at ($0.43) EPS, Q3 2027 earnings at ($0.40) EPS, Q4 2027 earnings at ($0.41) EPS, FY2027 earnings at ($1.67) EPS, FY2028 earnings at ($0.85) EPS, FY2029 earnings at ($1.04) EPS and FY2030 earnings at $1.13 EPS.

DTIL has been the subject of a number of other research reports. Weiss Ratings reissued a "sell (d-)" rating on shares of Precision BioSciences in a report on Tuesday, November 3rd. Wall Street Zen raised Precision BioSciences from a "sell" rating to a "hold" rating in a research report on Saturday. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $32.25.

Precision BioSciences Stock Performance

NASDAQ:DTIL opened at $10.60 on Monday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 10.47 and a current ratio of 10.47. Precision BioSciences has a one year low of $3.53 and a one year high of $11.29. The business's 50-day simple moving average is $6.90 and its 200 day simple moving average is $6.62. The stock has a market cap of $296.16 million, a price-to-earnings ratio of -8.55 and a beta of 1.34.

Precision BioSciences (NASDAQ:DTIL - Get Free Report) last announced its earnings results on Tuesday, November 3rd. The company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.85) by $0.57. Precision BioSciences had a negative return on equity of 56.69% and a negative net margin of 96.73%. The company had revenue of $1.25 million during the quarter, compared to the consensus estimate of $1.38 million.

Institutional Investors Weigh In On Precision BioSciences

A number of institutional investors have recently modified their holdings of DTIL. Russell Investments Group Ltd. raised its position in shares of Precision BioSciences by 4,217.9% during the 3rd quarter. Russell Investments Group Ltd. now owns 82,818 shares of the company's stock worth $518,000 after purchasing an additional 80,900 shares during the period. Engineers Gate Manager LP acquired a new position in Precision BioSciences during the 2nd quarter valued at about $164,000. Squarepoint Ops LLC boosted its stake in Precision BioSciences by 212.7% during the 2nd quarter. Squarepoint Ops LLC now owns 137,106 shares of the company's stock valued at $1,078,000 after purchasing an additional 93,258 shares during the period. Corient Private Wealth LP grew its position in Precision BioSciences by 70.4% in the 2nd quarter. Corient Private Wealth LP now owns 245,058 shares of the company's stock worth $1,926,000 after purchasing an additional 101,206 shares during the last quarter. Finally, Bank of New York Mellon Corp bought a new position in Precision BioSciences in the 2nd quarter worth about $467,000. Institutional investors own 37.99% of the company's stock.

Key Precision BioSciences News

Here are the key news stories impacting Precision BioSciences this week:

• Positive Sentiment: HC Wainwright raised its FY2026 EPS estimate to a loss of $2.01 from a loss of $3.47, and its Q4 2026 estimate to a loss of $0.72 from a loss of $1.20. The less severe projected losses could support sentiment about near-term finances. The analyst retained a Buy rating. Precision BioSciences analyst estimates
• Neutral Sentiment: Wall Street Zen upgraded Precision BioSciences to Hold. This is a more favorable rating than a Sell, but it does not signal a bullish outlook. Precision BioSciences upgraded to Hold
• Negative Sentiment: HC Wainwright lowered EPS estimates across 2027–2029, including its FY2027 estimate to a loss of $1.67 from $1.55 and FY2028 to a loss of $0.85 from $0.75. Its FY2029 loss estimate widened to $1.04 from $0.95, while its FY2030 profit estimate fell to $1.13 from $1.24. These revisions suggest a weaker longer-term earnings outlook, despite the Buy rating. Precision BioSciences analyst estimates

Precision BioSciences Company Profile

Precision BioSciences, Inc is a biotechnology company developing gene-editing medicines using its proprietary ARCUS platform. ARCUS is based on engineered DNA-cutting enzymes designed to make targeted changes to genetic material, with the potential to remove, insert or correct DNA sequences in human cells.

The company's research and development activities have focused primarily on in vivo gene editing, in which therapeutic editing components are delivered directly into the body. Its development programs have included potential treatments for conditions such as chronic hepatitis B infection, Duchenne muscular dystrophy and certain rare genetic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.